M
Overview
myDNA offers direct-to-consumer DNA tests for precision health, focusing on pharmacogenomics to tailor medication choice and dosing. It also provides nutrigenomics insights for nutrition and wellness, with results reported to the patient’s healthcare provider. Tests are cheek-swab kits sold online and through pharmacies, with global expansion via a merger and ownership by DBG Group. Goal: use genetic information to improve medication effectiveness and overall wellbeing.
Work here?Claim your company
Simplify's take
What believers are saying
- myDNA's November 2026 site now lists DBG Health ownership, implying stronger backing.
- FamilyTreeDNA switched to NGS in March 2026, improving product quality and margins.
- Bupa free PGx kits and Glasgow partnerships can convert clinical pilots into recurring demand.
What critics are saying
- Revelio shows headcount fell to 208 in 2026, signaling slow growth.
- myDNA competes against 23andMe, GeneSight, and hospital labs with stronger brands.
- Consumer genetics commoditization and reimbursement failures can crush myDNA's standalone economics.
What makes myDNA unique
- Gene by Gene gives myDNA in-house sequencing and genealogy infrastructure.
- November 2026 Glasgow lab launch expands global clinical testing and turnaround capacity.
- Bupa partnership and University of Glasgow Phoenix Trial validate pharmacogenomics adoption.
Help us improve and share your feedback! Did you find this helpful?